Serenoa repens (Permixon®) inhibits the 5α-reductase activity of human prostate cancer cell lines without interfering with PSA expression

International Journal of Cancer

Volumn 114, Issue 2, 2005, Pages 190-194

  Habib, Fouad K ^a,b   Ross, Margaret ^a   Ho, Clement K H ^a   Lyons, Valerie ^a   Chapman, Karen ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Androgen receptor responsive genes; Phytotherapy; Prostate cancer; Transcriptional activity

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ISOENZYME; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE; HORMONE ACTION; HUMAN; HUMAN CELL; NONHUMAN; PHYTOTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BINDING; REPORTER GENE; SABAL; TRANSCRIPTION INITIATION; TUMOR GROWTH;

ANDROGEN ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; DIHYDROTESTOSTERONE; FINASTERIDE; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SERENOA; TESTOSTERONE; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 13244291442     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20701     Document Type: Article

References (22)

1. Bonham M, Arnold H, Montgomery B, Nelson PS. Molecular effects of the herbal compound PC-SPES: identification of activity pathways in prostate carcinoma. Cancer Res 2002;62:3920-4.
2. Bayne C, Donnelly F, Ross M, Habib, FK. Serenoa repens (Permixon): a 5α-reductase types I and II inhibitor-new evidence in a co-culture model of BPH. Prostate 1999;40:232-41.
3. Plosker GL, Brogden RN. Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Ageing 1996;9:379-95.
4. Ravenna L, Di Silverio F, Russo MA, Salvatori L, Morgante E, Morrone S, Cerdillo MR, Russo A, Frati L, Gulino A, Petrangeli E. Effects of the lipidosterolic extract of Serenoa repens (Permixon®) on human prostatic cell lines. Prostate 1996;29:219-30.
5. Wang LG, Liu XM, Kreis W, Budman, DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells. Cancer Res 1997;57:714-9.
6. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: a decade of discovery-what we have learnt and where we are going. J Urol 1999;162:293-306.
7. Dreikorn K, Lowe F, Borkowski A, Buck C, Braeckman D, Chopin D, Denis L, Ferrari P, Habib FK, Perrin P. Other medical therapies. In: Chatelain C, Denis L, Foo KT, Khuory S, McConnell J, eds. Benign prostatic hyperplasia. Plymouth, UK: Health Publication, 2001. 481-511.
8. Bayne CW, Ross M, Donnelly F, Habib FK. Selectivity and specificity of the actions of the lipido-sterolic extract of Serenoa repens (Permixon) for the prostate. J Urol 2000;164:876-81.
9. Cleutjens KBJM, van der Korput AGM, van Eekelen CCEM, van Rooij HCJ, Faber PW, Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997;11:148-61.
10. Brinkmann AO, Faber PW, van Rooij HCJ, Kuiper GGJM, Ris C, Klaassen P, van der Korput JAGM, Voorhorst MM, van Laar JH, Mulder E, Trapman J. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem 1989;34:307-10.
11. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA 1990;87:3640-4.
12. Williams LJ, Lyons V, MacLeod I, Rajan V, Darlington GJ, Poli V, Seckl JR, Chapman KE. C/EBP regulates hepatic transcription of 11 β- hydroxysteroid dehydrogenase type I. A novel mechanism for cross talk between the C/EBP ad glucocorticoid signalling pathways. J Biol Chem 2000;275:30232-9.
13. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage ST4. Nature 1970;227;680-5.
14. Montgomery BT, Young CY-F, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJ. Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate 1992;21:63-73.
15. Cleutjens KBJM, van der Korput AGM, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW, Trapman J. A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol 1997;11:1256-65.
16. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LNCaP human prostatic cancer cell line in vitro. Urology 1995;45:282-90.
17. Habib FK, Ross M, Tate R, Chisholm GD. Differential effect of finasteride on the androgen concentrations in benign tissular hyperplasia. Clin Endocrinol 1997;46:137-44.
18. Zhu Y-S, Cai L-Q, You X, Cordero JJ, Huang Y, Imperato-McGinley J. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. J Androl 2003;24:681-7.
19. Boyle P, Lowe F, Robertson C, Roehborn CG. Meta analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000;55:533-9.
20. Habib FK, Ross M, Bayne CW, Grigor K, Buck AC, Chapman K. The localisation and expression of 5α-reductase type I and type II mRNA in human hyperplastic prostate and in prostate primary cultures. J Endocrinol 1998;156:509-17.
21. Klocker H, Culig Z, Eder I, Nespler-Manardi C, Iotova I, Hobisch A, Bartsch G. Ligand-dependent and independent activation of the androgen receptor and implications for therapy. In: Habib FK, ed. The prostate: new concepts and developments. London; Taylor & Francis, 2004. 71-82.
22. Mora GR, Tindall D. Ligand dependent and independent activation of the androgen receptor. In: Chung LWK, Isaacs WB, Simmons JW, eds. Prostate cancer: biology, genetics and the new therapeutics. Totowa, NJ: Humana, 2001. 219-39.